Arlene O. Siefker-Radtke, MD | Authors

Articles

Discussion on Trial Investigating Erdafitinib in Patients With Urothelial Cancer

June 08, 2018

Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at MD Anderson Cancer Center, discusses the results presented at the 2018 ASCO Annual Meeting from a phase II cohort investigating erdafitinib in previously treated patients with urothelial cancer. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that targets FGFR 1 through 4 and has previously shown promising activity.